Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting

ABSTRACT

Introduction

At the 65th American Society of Hematology (ASH) 2023 Annual Meeting, the latest advancements in CD20×CD3 BsAbs for B-cell lymphoma (BCL) were highlighted, particularly in relapsed/refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL).

Areas covered

This summary highlights some of the major studies on CD20×CD3 BsAbs for BCL.

Expert Opinion/Commentary

CD20×CD3 is the most widely studied BsAb, with promising results in patients with R/R DLBCL and R/R FL ≥ two prior lines of systemic therapy. Trials with the first line of B-cell lymphoma also revealed promising results. Hopefully, BsAb monotherapy or BsAb-containing regimens may become the standard therapy in patients with FL and DLBCL.

KEYWORDS:

• Bispecific antibodies
• B-cell lymphoma
• diffuse large B-cell lymphoma
• follicular lymphoma
• immunotherapy

Abbreviations

ASH	=	American Society of Hematology
BCL	=	B-cell lymphoma
BsAbs	=	bispecific antibodies
CAR T-cell	=	chimeric antigen receptor T-cell
CMR	=	complete metabolic response
CR	=	complete response
CRS	=	cytokine release syndrome
DLBCL	=	diffuse large B cell lymphoma
FL	=	follicular lymphoma
LBCL	=	large B-cell lymphoma
ORR	=	overall response rate
OS	=	overall survival
R/R	=	relapsed or refractory

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contribution statement

J Yu designed and directed the manuscript. H Sun, H Xing and L Han wrote the manuscript draft. Y Liu and J Yu revised the manuscript. Y Song and Z Jiang provided resources. All authors reviewed and approved the final manuscript.

Acknowledgments

The authors would like to thank all the patients and their families for participating in clinical trials testing the drugs mentioned in this review.

Correction Statement

This article has been corrected with minor changes. These changes do not impact the academic content of the article.

Additional information

Funding

This paper was funded by the Zhengzhou Municipal Science and Technology Bureau project number XTCX2023010, and Talent Research Fund of the First Affiliated Hospital of Zhengzhou University, granted to J Yu, the National Nature Science Foundation of China [grant number 82270225 granted to L Han].